Market influence meaning

In this issue: UK mergers UK antitrust UK subsidy control UK competition policy EU antitrust EU mergers EU State aid EU market studies New and updated content Daily and weekly news alerts Caselex UK mergers Government consults on further changes to the draft Enterprise Act 2002 (Mergers Involving Newspaper Enterprises and Foreign Powers) (No 2) Regulations The Department for Culture, Media and Sport (DCMS) has published a consultation on proposed further amendments to the Enterprise Act 2002 (Mergers Involving Newspaper Enterprises and Foreign Powers) Regulations 2025 (the Regulations). Through changes to the Enterprise Act 2002, the Digital Markets, Competition and Consumers Act 2024 introduced a foreign state intervention (FSI) regime for newspapers and periodic news magazines, preventing foreign state ownership, control, or influence over these publications. The Regulations carry forward the government’s decision to provide narrow exemptions to the FSI framework. Under the proposals, defined state-owned investors (SOIs) could hold up to...

The survey gathered input from 14 of the 28 insurers listed by the Solicitors Regulation Authority (SRA) for the 2024 indemnity year. Conducted anonymously via Qualtrics and in partnership with the International Underwriting Association, it found that 38% of respondents foresaw potential difficulties at renewal, although the exact tally was not provided. Browne Jacobson reported that solicitors began considering leaving the PII market after the Court of Appeal’s January 2024 decision in Discovery Land Co LLC and others v Axis Specialty Europe SE. The firm noted that the ruling heightened worries about tightly drawn aggregation of claims under the SRA’s minimum terms and conditions, which influence the limit of indemnity. Ed Anderson, a partner at Browne Jacobson who deals with PII, ...

Public.Resource.Org and Right to Know v Commission and Others, Case C-588/21 What are the practical implications of this case? Although the dispute concerned four particular harmonised standards, the Court’s reasoning applies more widely to other harmonised standards as well. Where such standards are mandatory or create a presumption of conformity with safety requirements, there is a clear public interest in their disclosure, so the European Commission cannot refuse access by invoking the Article 4(2) exception in Regulation (EC) 1049/2001. Consequently, companies will be able to obtain harmonised standards to verify and ensure compliance with EU legislation without paying a fee; however, this may influence the business model of European standardisation organisations. What was the background? Under the European product safety rules, certain products can only be placed on the EU market if they satisfy safety requirements. Showing compliance with those requirements can often be an onerous exercise. Accordingly, the European legislator has provided for specific products (including, in this case, toys) that where a manufacturer follows...

For both the investing private equity fund and the target’s leadership, the prime lure of a private equity-backed buyout is the chance to crystallise a meaningful gain on exit. There are several potential paths to exit from such an investment, most typically: a trade sale to another company operating within the same sector, a flotation (IPO), or a secondary buyout (SBO). The ultimate route will hinge on considerations such as public market appetite for a listing and whether credible purchasers are available. Management often influence the decision, and may favour renewed private equity support via an SBO when the business model and prevailing market backdrop align. A secondary buyout (SBO) is, in essence, a private equity-backed acquisition of a company that has already undergone a private equity-backed buyout. In an SBO, the existing private equity owner exits its stake, though the current management team can remain in post afterwards. Alternatively, fresh management might be appointed, or a blend of old and new...

NOTE—to see whether notification thresholds in the Netherlands and across the globe are met, see further: Where to Notify 1. Have there been any recent developments regarding the Dutch merger control regime and are any updates/developments expected in the coming year? Are there any other ‘hot’ merger control issues with the ACM? Media Following the Authority for Consumers and Market’s (ACM) prohibition of RTL’s proposed purchase of Talpa (two players in the Dutch television media market) on 30 January 2023, DPG Media announced plans to acquire RTL and filed the deal with the ACM. On 17 May 2024, the ACM concluded that the transaction merited deeper scrutiny and therefore referred the matter to the second (‘licence’) phase. On 18 July 2024, the parties submitted their application for the requisite licence. On 27 June 2025, the ACM issued conditional clearance for the merger in its DPG/RTL decision, imposing stringent behavioural commitments. Notably, the ACM factored media plurality into its competition analysis—an innovative development in Dutch merger control practice...

Prepared in collaboration with Bilal Shaukat, partner, and Shahbakht Pirzada, associate partner, at Pakistani law firm RIAA Barker Gillette, on key issues concerning merger control in Pakistan. Note—to check whether notification thresholds in Pakistan and across the globe are satisfied, see Where to Notify. 1. Have there been any recent developments regarding the Pakistani merger control regime and are any updates/developments expected in the coming year? Are there any other ‘hot’ merger control issues in Pakistan? The Competition Commission of Pakistan (CCP) has recently issued the Competition Exemption Regulations 2020 (2020 Regulations). These Regulations set out the procedure for seeking an exemption from a prohibited agreement. The Competition Act 2010 (the Act) forbids undertakings and associations of undertakings from entering into prohibited agreements. Prohibited agreements—or, for associations of undertakings, decisions—concern the production, distribution, acquisition or control of goods, or the supply of services, whose object or effect is the prevention, restriction or reduction of competition in the relevant market...

Every medicinal product in the EU undergoes rigorous, systematic testing and evaluation of its quality, effectiveness and safety before it is authorised for use. After it reaches the market, continuous surveillance ensures that any factor which might influence a medicine’s safety profile is identified and evaluated carefully, and that appropriate actions are taken when needed. This ongoing monitoring is known as pharmacovigilance in the EU...